Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Accuracy and Errors in Hypothesis Testing01:13

Accuracy and Errors in Hypothesis Testing

593
Hypothesis testing is a fundamental statistical tool that begins with the assumption that the null hypothesis H0 is true. During this process, two types of errors can occur: Type I and Type II. A Type I error refers to the incorrect rejection of a true null hypothesis, while a Type II error involves the failure to reject a false null hypothesis.
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
593
Expected Frequencies in Goodness-of-Fit Tests01:19

Expected Frequencies in Goodness-of-Fit Tests

8.7K
A goodness-of-fit test is conducted to determine whether the observed frequency values are statistically similar to the frequencies expected for the dataset. Suppose the expected frequencies for a dataset are equal such as when predicting the frequency of any number appearing when casting a die. In that case, the expected frequency is the ratio of the total number of observations (n)  to the number of categories (k).
8.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.4K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.4K
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

321
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
321
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

520
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
520
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

311
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-Existent Endometrial and Fallopian Tube Carcinoma, Molecular and Pathological Features for Risk Stratification.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Recommendations for Pathologist-Led Deployment of Artificial Intelligence Tools as Laboratory-Developed Tests.

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

"HER2-Low" and the Challenge of Repurposing Legacy HER2 IHC Biomarker Assays.

Current oncology (Toronto, Ont.)·2026
Same author

Coexistent Endometrial and Ovarian Carcinoma: Terminology, Clinicopathological Features, and Clinical Significance.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026
Same author

Despite simplified diagnostic criteria, intraobserver and interobserver variability remain in the interpretation of colorectal serrated polyps.

Histopathology·2026
Same author

Substratification of mismatch repair deficient endometrial cancers based on mechanism of MMR loss can provide prognostic and predictive refinement.

Gynecologic oncology·2026

Related Experiment Video

Updated: Jan 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing.

Carol C Cheung1,2, Hyun J Lim3, John Garratt4

  • 1Department of Pathology, Laboratory Medicine Program, University Health Network.

Applied Immunohistochemistry & Molecular Morphology : AIMM
|February 22, 2019
PubMed
Summary

External quality assurance for PD-L1 testing presents challenges. Applying "fit-for-purpose" principles to proficiency testing (PT) runs enhances patient safety by improving diagnostic accuracy assessment for immunohistochemistry assays.

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.2K

Related Experiment Videos

Last Updated: Jan 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.2K

Area of Science:

  • Oncology
  • Pathology
  • Clinical Diagnostics

Background:

  • PD-L1 testing via immunohistochemistry (IHC) poses significant challenges for clinical laboratories and external quality assurance (EQA) programs.
  • Proficiency testing (PT) for predictive biomarkers necessitates a "fit-for-purpose" approach at all stages, from design to reporting.

Purpose of the Study:

  • To explore approaches for sample design and result analysis in PD-L1 PT runs to enhance patient safety.
  • To apply "fit-for-purpose" principles to PD-L1 PT runs, ensuring accurate assessment of diagnostic assays.

Main Methods:

  • Canadian Immunohistochemistry Quality Control (CIQC) conducted educational PT runs using unstained slides with tissue cores from 104 primary NSCLC and tonsil tissues.
  • Laboratories tested tissues with their current PD-L1 assays.
  • Diagnostic sensitivity and specificity were calculated against "gold standards" using the "3D" approach (drug-disease-diagnostic assay).

Main Results:

  • Significant variation in the performance (accuracy) of diagnostic assays was observed, dependent on the selection of "fit-for-purpose" gold standards and cut-off points.
  • The study highlighted the impact of chosen standards and cut-offs on assay performance evaluation.

Conclusions:

  • "Fit-for-purpose" in PD-L1 PT requires clearly declared run purposes, designated purpose-specific gold standards, and PT materials designed for accurate diagnostic assessment.
  • Implementing "fit-for-purpose" principles is crucial for reliable PD-L1 testing and improved patient safety.